Clinical validation of the Swedish version of Dyspnoea-12 instrument in outpatients with cardiorespiratory disease

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Clinical validation of the Swedish version of Dyspnoea-12 instrument in outpatients with cardiorespiratory disease. / Sundh, Josefin; Bornefalk, Hans; Sköld, Carl Magnus; Janson, Christer; Blomberg, Anders; Sandberg, Jacob; Bornefalk-Hermansson, Anna; Igelström, Helena; Ekström, Magnus.

I: BMJ Open Respiratory Research, Vol. 6, Nr. 1, e000418, 2019.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

APA

CBE

MLA

Vancouver

Author

Sundh, Josefin ; Bornefalk, Hans ; Sköld, Carl Magnus ; Janson, Christer ; Blomberg, Anders ; Sandberg, Jacob ; Bornefalk-Hermansson, Anna ; Igelström, Helena ; Ekström, Magnus. / Clinical validation of the Swedish version of Dyspnoea-12 instrument in outpatients with cardiorespiratory disease. I: BMJ Open Respiratory Research. 2019 ; Vol. 6, Nr. 1.

RIS

TY - JOUR

T1 - Clinical validation of the Swedish version of Dyspnoea-12 instrument in outpatients with cardiorespiratory disease

AU - Sundh, Josefin

AU - Bornefalk, Hans

AU - Sköld, Carl Magnus

AU - Janson, Christer

AU - Blomberg, Anders

AU - Sandberg, Jacob

AU - Bornefalk-Hermansson, Anna

AU - Igelström, Helena

AU - Ekström, Magnus

PY - 2019

Y1 - 2019

N2 - Introduction Breathlessness is the cardinal symptom in both cardiac and respiratory diseases, and includes multiple dimensions. The multidimensional instrument Dyspnoea-12 has been developed to assess both physical and affective components of breathlessness. This study aimed to perform a clinical validation of the Swedish version of Dyspnoea-12 in outpatients with cardiorespiratory disease. Methods Stable outpatients with cardiorespiratory disease and self-reported breathlessness in daily life were recruited from five Swedish centres. Assessments of Dyspnoea-12 were performed at baseline, after 30-90 min and after 2 weeks. Factor structure was tested using confirmatory factor analysis and internal consistency using Cronbach's alpha. Test-retest reliability was analysed using intraclass correlation coefficients (ICCs). Concurrent validity at baseline was evaluated by examining correlations with lung function and several instruments for the assessment of symptoms and health status. Results In total, 182 patients were included: with the mean age of 69 years and 53% women. The main causes of breathlessness were chronic obstructive pulmonary disease (COPD; 25%), asthma (21%), heart failure (19%) and idiopathic pulmonary fibrosis (19%). Factor analysis confirmed the expected underlying two-component structure with two subdomains. The Dyspnoea-12 total score, physical subdomain score and affective subdomain scores showed high internal consistency (Cronbach's alpha 0.94, 0.84 and 0.80, respectively) and acceptable reliability after 2 weeks (ICC total scores 0.81, 0.79 and 0.73). Dyspnoea-12 showed concurrent validity with the instruments modified Medical Research Council scale, COPD Assessment Test, European Quality of Life-Five Dimensions-Five levels, the Functional Assessment of Chronic Illness Therapy-Fatigue, the Hospital Anxiety and Depression Scale, and with forced expiratory volume in 1 s in percentage of predicted value. The results were consistent across different cardiorespiratory conditions. Conclusion The Dyspnoea-12 is a valid instrument for multidimensional assessment of breathlessness in Swedish patients with cardiorespiratory diseases.

AB - Introduction Breathlessness is the cardinal symptom in both cardiac and respiratory diseases, and includes multiple dimensions. The multidimensional instrument Dyspnoea-12 has been developed to assess both physical and affective components of breathlessness. This study aimed to perform a clinical validation of the Swedish version of Dyspnoea-12 in outpatients with cardiorespiratory disease. Methods Stable outpatients with cardiorespiratory disease and self-reported breathlessness in daily life were recruited from five Swedish centres. Assessments of Dyspnoea-12 were performed at baseline, after 30-90 min and after 2 weeks. Factor structure was tested using confirmatory factor analysis and internal consistency using Cronbach's alpha. Test-retest reliability was analysed using intraclass correlation coefficients (ICCs). Concurrent validity at baseline was evaluated by examining correlations with lung function and several instruments for the assessment of symptoms and health status. Results In total, 182 patients were included: with the mean age of 69 years and 53% women. The main causes of breathlessness were chronic obstructive pulmonary disease (COPD; 25%), asthma (21%), heart failure (19%) and idiopathic pulmonary fibrosis (19%). Factor analysis confirmed the expected underlying two-component structure with two subdomains. The Dyspnoea-12 total score, physical subdomain score and affective subdomain scores showed high internal consistency (Cronbach's alpha 0.94, 0.84 and 0.80, respectively) and acceptable reliability after 2 weeks (ICC total scores 0.81, 0.79 and 0.73). Dyspnoea-12 showed concurrent validity with the instruments modified Medical Research Council scale, COPD Assessment Test, European Quality of Life-Five Dimensions-Five levels, the Functional Assessment of Chronic Illness Therapy-Fatigue, the Hospital Anxiety and Depression Scale, and with forced expiratory volume in 1 s in percentage of predicted value. The results were consistent across different cardiorespiratory conditions. Conclusion The Dyspnoea-12 is a valid instrument for multidimensional assessment of breathlessness in Swedish patients with cardiorespiratory diseases.

KW - asthma

KW - breathlessness

KW - COPD

KW - dyspnoea

KW - heart failure

KW - idiopathic pulmonary fibrosis

KW - internal consistency, reliability, concurrent validity

KW - multidimensional

U2 - 10.1136/bmjresp-2019-000418

DO - 10.1136/bmjresp-2019-000418

M3 - Article

VL - 6

JO - BMJ Open Respiratory Research

JF - BMJ Open Respiratory Research

SN - 2052-4439

IS - 1

M1 - e000418

ER -